NASDAQ:HOLXHologic Stock Price, Forecast & News

$53.00

+0.68 (+1.30 %)

(As of 05/29/2020 04:00 PM ET)

Add

Compare

Today's Range

$51.29

Now: $53.00▼

$53.18

50-Day Range

$39.38

MA: $48.23▼

$53.98

52-Week Range

$26.49

Now: $53.00▼

$55.25

Volume3.64 million shs

Average Volume2.32 million shs

Market Capitalization$13.69 billion

P/E Ratio23.14

Dividend YieldN/A

Beta1.44

Hologic, Inc., a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health. The company offers Aptima molecular diagnostic assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assay technologies, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test products. It also provides breast imaging and analytics products, such as 2D and 3D mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, and breast biopsy and biopsy site markers, as well as localization, specimen radiology, ultrasound, and connectivity solutions. In addition, the company offers Selenia Dimensions and 3Dimensions gantries for performing 2D and tomosynthesis image acquisition and display; C-View and Intelligent 2D software products; SecurView Workstations; computer aided detection systems; and stereotactic breast biopsy systems. Further, it provides SculpSure, PicoSure, and MonaLisa Touch aesthetic treatment systems; TempSure, a radio frequency energy sourced platform; and MedLite and other products, and system components for medical aesthetics. Additionally, the company offers NovaSure, an endometrial ablation system to treat women suffering from abnormal uterine bleeding; MyoSure surgical products for removal of fibroids, and uterine polyps and other pathology; and Horizon DXA System and Fluoroscan Insight FD skeletal health products. It sells its products through direct sales and service forces, and a network of independent distributors and sales representatives. The company was founded in 1985 and is headquartered in Marlborough, Massachusetts.

Beat the Market (BTM) Rank^™

2.3 Analyst's Opinion

Consensus Rating
Hologic has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 10 buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $55.80, Hologic has a potential upside of 5.3% from its current price of $53.00.
Amount of Analyst Coverage
Hologic has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.8 Community Rank

Outperform Votes
Hologic has received 764 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Hologic has received 624 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Hologic has received 55.04% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Hologic and other stocks. Vote “Outperform” if you believe HOLX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HOLX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Hologic does not currently pay a dividend.
Dividend Growth
Hologic does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Hologic insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,185,194.00 in company stock.
Percentage Held by Insiders
Only 1.00% of the stock of Hologic is held by insiders.
Percentage Held by Institutions
92.45% of the stock of Hologic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9 Earnings and Valuation

Earnings Growth
Earnings for Hologic are expected to grow by 25.99% in the coming year, from $2.27 to $2.86 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Hologic is 23.14, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.34.
Price to Earnings Ratio vs. Sector
The P/E ratio of Hologic is 23.14, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 24.89.
Price to Earnings Growth Ratio
Hologic has a PEG Ratio of 3.32. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Hologic has a P/B Ratio of 6.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.60 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry X-ray apparatus & tubes

Sub-IndustryHealth Care Equipment

SectorMedical

Current SymbolNASDAQ:HOLX

Previous Symbol

CUSIP43644010

CIK859737

Webwww.hologic.com

Phone508-263-2900

Debt

Debt-to-Equity Ratio1.32

Current Ratio1.31

Quick Ratio1.04

Price-To-Earnings

Trailing P/E Ratio23.14

Forward P/E Ratio23.35

P/E Growth3.32

Sales & Book Value

Annual Sales$3.37 billion

Price / Sales4.06

Cash Flow$4.20 per share

Price / Cash Flow12.62

Book Value$8.10 per share

Price / Book6.54

Profitability

EPS (Most Recent Fiscal Year)$2.43

Net Income$-203,600,000.00

Net Margins18.53%

Return on Equity30.49%

Return on Assets10.14%

Miscellaneous

Employees6,478

Outstanding Shares258,210,000

Market Cap$13.69 billion

Next Earnings Date7/29/2020 (Estimated)

OptionableOptionable

Receive HOLX News and Ratings via Email

Sign-up to receive the latest news and ratings for HOLX and its competitors with MarketBeat's FREE daily newsletter.

Hologic (NASDAQ:HOLX) Frequently Asked Questions

How has Hologic's stock been impacted by COVID-19 (Coronavirus)?

Hologic's stock was trading at $43.78 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, HOLX stock has increased by 21.1% and is now trading at $53.00. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Hologic?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last year. There are currently 5 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Hologic.

When is Hologic's next earnings date?

Hologic is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Hologic.

How were Hologic's earnings last quarter?

Hologic, Inc. (NASDAQ:HOLX) released its quarterly earnings results on Wednesday, April, 29th. The medical equipment provider reported $0.57 earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of $0.57. The medical equipment provider earned $756.10 million during the quarter, compared to analysts' expectations of $756.10 million. Hologic had a return on equity of 30.49% and a net margin of 18.53%. During the same period last year, the firm earned $0.58 EPS. View Hologic's earnings history.

What guidance has Hologic issued on next quarter's earnings?

Hologic updated its second quarter 2020 Pre-Market earnings guidance on Tuesday, April, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $756.1-756.1 million, compared to the consensus revenue estimate of $756.88 million.

What price target have analysts set for HOLX?

15 analysts have issued 12 month target prices for Hologic's shares. Their forecasts range from $43.00 to $62.00. On average, they expect Hologic's stock price to reach $55.80 in the next twelve months. This suggests a possible upside of 5.3% from the stock's current price. View analysts' price targets for Hologic.

What are Wall Street analysts saying about Hologic stock?

Here are some recent quotes from research analysts about Hologic stock:

1. According to Zacks Investment Research, "In recent times, Hologic registered strong top-line growth led by robust performances within majority of its businesses. In the last reported quarter, organic revenue growth against the toughest comparable of the year, significantly outdid Hologic’s projections. Continued solid uptake of Aptima women's health assays and consistent expansion of global installed bases of Genius 3D mammography systems and Panther instruments are encouraging. It put up a robust first quarter fiscal 2020 show with in-line earnings and revenues ahead of expectations. However, the contractions in both margins during the quarter are concerning. Difficult macroeconomic conditions due to coronavirus outbreak and foreign exchange fluctuations are other headwinds trailing the company. Overall, Hologic has been underperforming its industry over the past three months." (4/28/2020)
2. Canaccord Genuity analysts commented, "We look for greater evidence for Hologic to find a solution to its declining gross margins and we need more time to get confident that Cynosure has bottomed. Nevertheless, near mid-single-digit growth and effective capital allocation (buybacks and tuck-in deals) are warming us up to the stock as HOLX delivered a 2% top-line beat, 2 cent bottom-line beat, and raised its FY top- and bottom-line guide. That said, its FY’19 raised" revenue is less than the FQ3 $17M beat (FX headwinds being one factor), a consistent trend of setting a low bar for the next reporting quarter and essentially not raising its underlying baseline guide. We reiterate our HOLD, PT to $52. FQ3 beat. (+3.4% rep, +4.7% FXN) exceeded our/Street’s $835ME and adj." (8/1/2019)
3. Needham & Company LLC analysts commented, "FDA’s latest monthly Act (MQSA) statistics were published on 7/1/19. The number of digital breast tomosynthesis (DBT) units increased by 92 during June which represents a 30.8% Y/Y decrease. DBT unit penetration increased to 37.3% from 37.0% last month and facility penetration increased to 62.1% from 61.4% last month. More importantly, DBT units placements were up 2.7% quarter-to-date (QTD) in 2Q19 vs. 2Q18. We note that HOLX’s 3D mammography sales are less than 13% of its total sales. Please contact your Needham salesperson for a copy of our MQSA spreadsheet." (7/10/2019)

Has Hologic been receiving favorable news coverage?

Media stories about HOLX stock have trended negative this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Hologic earned a news sentiment score of -2.6 on InfoTrie's scale. They also assigned news coverage about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutHologic.

Are investors shorting Hologic?

Hologic saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 4,110,000 shares, a decline of 5.9% from the April 30th total of 4,370,000 shares. Based on an average trading volume of 3,090,000 shares, the days-to-cover ratio is presently 1.3 days. Currently, 1.6% of the shares of the stock are sold short. View Hologic's Current Options Chain.

Who are some of Hologic's key competitors?

Some companies that are related to Hologic include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Steris (STE), Masimo (MASI) and Insulet (PODD). View all competitors.

What other stocks do shareholders of Hologic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hologic investors own include AbbVie (ABBV), Starbucks (SBUX), Walt Disney (DIS), Johnson & Johnson (JNJ), Alibaba Group (BABA), Bank of America (BAC), NVIDIA (NVDA), salesforce.com (CRM), Medtronic (MDT) and Paypal (PYPL).

Who are Hologic's key executives?

Hologic's management team includes the following people:

Mr. Stephen P. MacMillan, Chairman, CEO & Pres (Age 55)
Ms. Karleen M. Oberton, Chief Financial Officer (Age 49)
Mr. John M. Griffin, Gen. Counsel (Age 58)
Mr. Peter J. Valenti III, Division Pres of Breast & Skeletal Health Solutions (Age 56)
Mr. Thomas A. West, Division Pres of Diagnostics Solutions (Age 55)

What is Hologic's stock symbol?

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

Who are Hologic's major shareholders?

Hologic's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.06%), State Street Corp (4.49%), Wellington Management Group LLP (2.49%), Geode Capital Management LLC (1.82%), Parnassus Investments CA (1.41%) and Nuveen Asset Management LLC (1.37%). Company insiders that own Hologic stock include Allison P Bebo, Benjamin Jordan Cohn, Christiana Stamoulis, John M Griffin, Karleen Marie Oberton, Peter J Valenti III, Sally Crawford and Stephen P Macmillan. View institutional ownership trends for Hologic.

Which institutional investors are selling Hologic stock?

HOLX stock was sold by a variety of institutional investors in the last quarter, including Parnassus Investments CA, AJO LP, BlackRock Inc., Wellington Management Group LLP, Two Sigma Investments LP, Geode Capital Management LLC, Korea Investment CORP, and UBS Group AG. Company insiders that have sold Hologic company stock in the last year include Benjamin Jordan Cohn, Christiana Stamoulis, John M Griffin, Karleen Marie Oberton, Peter J Valenti III, Sally Crawford, and Stephen P Macmillan. View insider buying and selling activity for Hologic.

Which institutional investors are buying Hologic stock?

HOLX stock was bought by a variety of institutional investors in the last quarter, including Teacher Retirement System of Texas, AQR Capital Management LLC, Balyasny Asset Management LLC, PGGM Investments, Federated Hermes Inc., Nuveen Asset Management LLC, Sumitomo Mitsui Trust Holdings Inc., and Acadian Asset Management LLC. View insider buying and selling activity for Hologic.

How do I buy shares of Hologic?

Shares of HOLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Hologic's stock price today?

One share of HOLX stock can currently be purchased for approximately $53.00.

How big of a company is Hologic?

Hologic has a market capitalization of $13.69 billion and generates $3.37 billion in revenue each year. The medical equipment provider earns $-203,600,000.00 in net income (profit) each year or $2.43 on an earnings per share basis. Hologic employs 6,478 workers across the globe.

What is Hologic's official website?

The official website for Hologic is www.hologic.com.

How can I contact Hologic?

Hologic's mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-263-2900 or via email at [email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff